ResearchTrends in HIV Prenatal Testing among Commercially Insured Pregnant Women in the United States, 2011–2022
ResearchQuantifying the number of people who would benefit from HIV pre-exposure prophylaxis (PrEP) in the United States: A comparison of behavioral, acquisition-risk based, and economic metrics
ResearchReal-World Positive Predictive Value and False Positive Rates of Laboratory-Based HIV Antigen/Antibody Testing by Age and Sex — United States, 2019–2024
Apr 30, 2026Journal ArticleSimplifying Testing for Human Immunodeficiency Virus During Pre-exposure Prophylaxis Monitoring.Written by 1 Roon author & 6 others Via Clinical Infectious Diseases
Feb 25, 2026Journal ArticleTrends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.Written by 1 Roon author & 8 others Via Clinical Infectious Diseases
ResearchHIV Preexposure Prophylaxis Prescriptions, Consent Laws, and Uptake Barriers Among Adolescents
ResearchClinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025
ResearchPrimary care screening for sexually transmitted infections in the United States from 2019 to 2021
ResearchLonger-acting preexposure prophylaxis product and delivery preferences among U.S. populations disproportionately affected by HIV: a discrete choice experiment
ResearchOut-of-pocket costs for PrEP ancillary services among U.S. commercially insured persons, 2017–2022
ResearchAntiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV — CDC Recommendations, United States, 2025